STOCK TITAN

Xencor Inc - XNCR STOCK NEWS

Welcome to our dedicated news page for Xencor (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Xencor's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Xencor's position in the market.

Rhea-AI Summary
Xencor, Inc. (NASDAQ:XNCR) announced its participation in multiple investor conferences in March 2024, including TD Cowen 44th Annual Health Care Conference, Leerink Partners Global Biopharma Conference, Jefferies Biotech on the Bay Summit, and Barclays Global Healthcare Conference. Live webcasts and replays of the presentations will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
conferences
-
Rhea-AI Summary
Xencor, Inc. reports financial results for Q4 and full year 2023, highlights clinical data on vudalimab for high-risk mCRPC patients, and outlines upcoming priorities and partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.06%
Tags
earnings
-
Rhea-AI Summary
Xencor, Inc. (XNCR) will report financial results for Q4 and full year 2023 on February 27, 2024. The company focuses on developing antibodies and cytokines for cancer and autoimmune diseases. A webcast and conference call will be held to discuss financial results and provide updates on vudalimab in prostate cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
conferences earnings
Rhea-AI Summary
Xencor, Inc. (NASDAQ:XNCR) announced that Bassil Dahiyat, Ph.D., president and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. Xencor is a clinical-stage biopharmaceutical company developing antibodies and cytokines for cancer and autoimmune diseases. The presentation will be available via webcast and archived for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
conferences
-
Rhea-AI Summary
Xencor, Inc. (NASDAQ:XNCR) announced that Dane Leone, CFA, has joined as senior vice president, corporate strategy. With 20 years of experience as a leading equity research analyst, Mr. Leone will support R&D leadership to enhance value across Xencor’s platform technologies by overseeing assessment and prioritization of current and future XmAb® drug candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.03%
Tags
none
-
Rhea-AI Summary
Xencor, Inc. (XNCR) to present at Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
conferences
Rhea-AI Summary
Xencor, Inc. (NASDAQ:XNCR) announces sale of financial interests from Alexion Pharmaceuticals, Inc. and MorphoSys AG to OMERS, receiving a $215 million payment. OMERS acquires royalties on global Ultomiris and Monjuvi sales, providing Xencor with additional financial flexibility and potential economic upside.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.01%
Tags
none
-
Rhea-AI Summary
Xencor, Inc. (NASDAQ:XNCR) Reports $215 Million Upfront from Royalty Transaction with OMERS Life Sciences, Announces Pipeline Decisions and Financial Results for Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.01%
Tags
earnings
-
Rhea-AI Summary
Xencor, Inc. presented data from multiple preclinical-stage programs at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. They are developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases. Xencor aims to submit an investigational new drug application for XmAb541, a bispecific antibody for ovarian cancer. They are also developing CD3 and CD28 T cell engaging bispecific antibodies against solid tumor targets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.49%
Tags
clinical trial
Rhea-AI Summary
Xencor, Inc. (NASDAQ: XNCR) will release its third quarter 2023 financial results on November 7, 2023, after the market closes. A webcast and conference call will be held at 4:30 p.m. ET to discuss the results and provide a corporate update. The live webcast can be accessed through the Company's website, and a recording will be available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
conferences earnings
Xencor Inc

Nasdaq:XNCR

XNCR Rankings

XNCR Stock Data

1.37B
55.23M
0.98%
105.63%
9.15%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Monrovia

About XNCR

antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product